tiprankstipranks
Rosetta Genomics (ROSGQ)
:ROSGQ
US Market
Holding ROSGQ?
Track your performance easily

Rosetta Genomics (ROSGQ) Stock Price & Analysis

62 Followers

ROSGQ Stock Chart & Stats


Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.15%99.85%
Insiders
Mutual Funds
0.15% Other Institutional Investors
99.85% Public Companies and
Individual Investors

ROSGQ FAQ

What was Rosetta Genomics’s price range in the past 12 months?
Currently, no data Available
What is Rosetta Genomics’s market cap?
Rosetta Genomics’s market cap is $6.00.
    When is Rosetta Genomics’s upcoming earnings report date?
    The company’s upcoming earnings report date is not yet available.
    How were Rosetta Genomics’s earnings last quarter?
    Currently, no data Available
    Is Rosetta Genomics overvalued?
    According to Wall Street analysts Rosetta Genomics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
      Does Rosetta Genomics pay dividends?
      Rosetta Genomics does not currently pay dividends.
      What is Rosetta Genomics’s EPS estimate?
      Rosetta Genomics’s EPS estimate for its next earnings report is not yet available.
      How many shares outstanding does Rosetta Genomics have?
      Rosetta Genomics has 5,930,000 shares outstanding.
        What happened to Rosetta Genomics’s price movement after its last earnings report?
        Currently, no data Available
        Which hedge fund is a major shareholder of Rosetta Genomics?
        Currently, no hedge funds are holding shares in ROSGQ
        ---

        Company Description

        Rosetta Genomics

        Rosetta Genomics Ltd. provides therapeutic, diagnostic product development and medical research services. The company develops and commercializes new diagnostic tests based on various genomics markers, including DNA, microRNA and protein biomarkers and using various technologies, including, qPCR, microarrays, next generation sequencing and fluorescence in situ hybridization. It offers proprietary microRNA technologies, such as Rosetta Cancer Origin, mi-KIDNEY, and RosettaGX Reveal Test. The company was founded by Isaac Bentwich on March 9, 2000 and is headquartered in Rehovot, Israel.
        ---
        Similar Stocks
        Company
        Price & Change
        Follow
        Advaxis
        Veracyte
        Qiagen
        Cyclacel Pharmaceuticals
        RegenXBio
        Bio-Path Holdings
        Popular Stocks
        ---
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis